

# Agenda

|                             |   |                              |                             |
|-----------------------------|---|------------------------------|-----------------------------|
| 會議時間<br><b>Meeting Time</b> | <b>5<sup>th</sup> Nov 2022</b>                  | 會議地點<br><b>Meeting Venue</b> | 台中日月千禧<br><b>5F - VEE 5</b> |
| 會議名稱<br><b>Meeting Name</b> | <b><i>International Hematology Congress</i></b> |                              |                             |

| 時間/ Time    | 議題/ Topic  | Speaker  | Moderator      |
|-------------|--|--|----------------|
| 14:00-14:30 | Registration   |  |                |
| 14:30-14:35 | Opening  | 周文堅 醫師<br>臺大醫院   |                |
| 14:35-15:10 | Treatment landscape of CML in 2022 and how immune effect optimize treatment outcome in CML                                     | Satu Mustjoki, MD<br>University of Helsinki,<br>Finland                        | 周文堅 醫師<br>臺大醫院 |
| 15:10-15:25 | Panel Discussion   | All  |                |
| 15:25-15:55 | The Immunomodulatory effects of BCR-ABL TKIs and long-term treatment outcome in patient with CML – Taiwan RWE                  | 劉益昌 醫師<br>高醫附醫   | 陳彩雲 醫師<br>成大醫院 |
| 15:55-16:25 | Activated naïve $\gamma\delta$ T cells accelerate deep molecular response to TKIs in patients with CML – Taiwan RWE            | 陳功深 醫師<br>馬偕醫院   | 侯信安 醫師<br>臺大醫院 |
| 16:25-16:35 | Panel Discussion   | All  |                |
| 16:35-16:45 | Coffee Break   |  |                |
| 16:45-17:15 | Optimal treatment strategy in patients with higher-risk MDS and with AML   | 蔡承宏 醫師<br>臺大醫院   | 滕傑林 醫師<br>台中榮總 |
| 17:15-17:50 | Navigating optimal treatment outcome from TKI-based induction therapy toward post-HSCT TKI maintenance in patient with Ph+ ALL | Farhad Ravandi, MD<br>University of Texas MD<br>Anderson Cancer Center,<br>USA | 葉士芃 醫師<br>中國附醫 |
| 17:50-18:10 | Panel Discussion   | All  |                |
| 18:10-18:20 | Closing  | 葉士芃 醫師<br>中國附醫   |                |
| 18:20-      | Dinner   | All  |                |

醫學會學分 (申請中)：中華民國血液及骨髓移植學會、中華民國血液病學會、台灣內科醫學會、中華民國癌症醫學會、台灣癌症安寧緩和醫學會

**This event is strictly for the invited Health Care Professionals only.**

**This event is not open to spouse, family member(s) or partner(s) of invited HCP and non-invited HCP(s).**

**Thank you for your kind understanding and co-operation.**

## **Foreign Speaker Introduction**

*International Hematology Congress – Leukemia on 5th November*

### **Satu Mustjoki, MD, Professor**

Professor of Translational Hematology, Univ. of Helsinki, Finland.  
Head of department, Helsinki University Hospital (HUH)  
Comprehensive Cancer Center, Helsinki Finland.  
Director of Translational Immunology Research Program, Faculty of  
Medicine, Univ. of Helsinki (UH), Finland



Our research group, the Hematology Research Unit Helsinki (HRUH), has examined the role of the immune system in chronic myeloid leukemia (CML) and revealed the novel immunomodulatory effects of tyrosine kinase inhibitors (TKIs). Our recent data has also highlighted the role of NK cells in maintaining the remission after TKI discontinuation. In CML we have developed a novel risk stratification model for predicting the current treatment goal of TKI therapy. The combination of immune markers seems to perform better than conventional risk scores warranting the testing of immunomodulatory drugs in future CML treatment aiming in the cure of patients.

### **Farhad Ravandi, MD, Professor**

Department of Leukemia, Division of Cancer Medicine, The  
University of Texas – MD Anderson Cancer Center  
, Texas, USA,



The Philadelphia (Ph) chromosome, a short chromosome 22, is the most frequent cytogenetic abnormality in adult patients with acute lymphoblastic leukemia (ALL). It occurs in approximately 20% to 30% of adults and in about 5% of children with this disease. The incidence rises with age and occurs in approximately 50% of patients older than 50 years. This section will review the optimal treatment strategy of Ph+ ALL with tyrosine kinase inhibitors (TKIs), including in induction therapy : how important of deeper response is in Ph+ ALL, how to choose treatment strategy in HSCT eligible and non-eligible pts; and Post-transplant treatment strategy : when to add on TKI for maintenance, what is the appropriate dosage of TKI and AE management in maintenance therapy.